SI3124018T1 - Oral formulations of deferasirox - Google Patents

Oral formulations of deferasirox Download PDF

Info

Publication number
SI3124018T1
SI3124018T1 SI201430621T SI201430621T SI3124018T1 SI 3124018 T1 SI3124018 T1 SI 3124018T1 SI 201430621 T SI201430621 T SI 201430621T SI 201430621 T SI201430621 T SI 201430621T SI 3124018 T1 SI3124018 T1 SI 3124018T1
Authority
SI
Slovenia
Prior art keywords
tablet
deferasirox
film
oral administration
administration according
Prior art date
Application number
SI201430621T
Other languages
English (en)
Slovenian (sl)
Inventor
Indrajit Ghosh
Jia-Ai Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50288212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3124018(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI3124018T1 publication Critical patent/SI3124018T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201430621T 2013-03-08 2014-03-06 Oral formulations of deferasirox SI3124018T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361774893P 2013-03-08 2013-03-08
US201361824435P 2013-05-17 2013-05-17
EP16188627.0A EP3124018B2 (en) 2013-03-08 2014-03-06 Oral formulations of deferasirox

Publications (1)

Publication Number Publication Date
SI3124018T1 true SI3124018T1 (en) 2018-04-30

Family

ID=50288212

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201430621T SI3124018T1 (en) 2013-03-08 2014-03-06 Oral formulations of deferasirox
SI201431064T SI2964202T1 (sl) 2013-03-08 2014-03-06 Peroralne formulacije deferasiroksa

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201431064T SI2964202T1 (sl) 2013-03-08 2014-03-06 Peroralne formulacije deferasiroksa

Country Status (41)

Country Link
US (4) US9283209B2 (enExample)
EP (2) EP3124018B2 (enExample)
JP (3) JP6434429B2 (enExample)
KR (2) KR20170045391A (enExample)
CN (1) CN105025886B (enExample)
AP (1) AP2015008668A0 (enExample)
AU (2) AU2014224198B2 (enExample)
BR (1) BR112015021254A2 (enExample)
CA (1) CA2890465A1 (enExample)
CL (1) CL2015002495A1 (enExample)
CR (1) CR20150467A (enExample)
CU (1) CU24348B1 (enExample)
CY (2) CY1120021T1 (enExample)
DK (2) DK2964202T3 (enExample)
DO (1) DOP2015000220A (enExample)
EA (1) EA031719B1 (enExample)
EC (1) ECSP15042897A (enExample)
ES (2) ES2708955T5 (enExample)
HR (2) HRP20190173T1 (enExample)
HU (2) HUE036921T2 (enExample)
IL (1) IL240797B (enExample)
JO (1) JO3570B1 (enExample)
LT (2) LT2964202T (enExample)
ME (1) ME03297B (enExample)
MX (1) MX361055B (enExample)
MY (1) MY170303A (enExample)
NI (1) NI201500126A (enExample)
NZ (1) NZ711179A (enExample)
PE (1) PE20151600A1 (enExample)
PH (1) PH12015501981A1 (enExample)
PL (2) PL2964202T3 (enExample)
PT (2) PT3124018T (enExample)
RS (2) RS56890B1 (enExample)
SA (1) SA515360425B1 (enExample)
SG (2) SG10201807204YA (enExample)
SI (2) SI3124018T1 (enExample)
TN (1) TN2015000393A1 (enExample)
TW (2) TWI625136B (enExample)
UY (1) UY35367A (enExample)
WO (1) WO2014136079A1 (enExample)
ZA (1) ZA201506060B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS56890B1 (sr) 2013-03-08 2018-04-30 Novartis Ag Formulacije deferasiroksa za oralnu upotrebu
US9866684B2 (en) * 2015-02-16 2018-01-09 Microsoft Technology Licensing, Llc Process for real-time data exchange between users on a phone call
WO2016167729A1 (en) * 2015-04-16 2016-10-20 Öğün Yusuf Toktamiş Dispersible tablets comprising deferasirox
EP3310354A4 (en) 2015-06-17 2018-12-12 Dispersol Technologies, LLC Improved formulations of deferasirox and methods of making the same
WO2017158559A1 (en) 2016-03-17 2017-09-21 Lupin Limited Compositions of deferasirox
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
CA3029543C (en) * 2016-07-05 2021-11-23 Jubilant Generics Limited Immediate release pharmaceutical composition of iron chelating agents
EP3518904A1 (en) 2016-09-30 2019-08-07 Synthon B.V. Pharmaceutical composition comprising deferasirox
CZ2017255A3 (cs) 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
TR201707764A2 (tr) * 2017-05-29 2018-12-21 Biofarma Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasiroksun bölünebilir tablet formları.
WO2019108156A1 (en) * 2017-11-28 2019-06-06 Biofarma Ilac Sanayi Ve Ticaret A.S. A scored tablet formulation comprising deferasirox in a film tablet form
KR20200113116A (ko) 2019-03-22 2020-10-06 주식회사 한국팜비오 데페라시록스를 포함하는 필름코팅정제
EP3854385A1 (en) * 2020-01-27 2021-07-28 ROS Therapeutics ApS Methotrexate dosage form
EP4052698A1 (en) * 2021-03-05 2022-09-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Film coated tablet comprising deferasirox
CN115154428B (zh) * 2022-09-06 2023-01-10 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法
WO2025242589A1 (en) 2024-05-21 2025-11-27 Chiesi Farmaceutici S.P.A. Pharmaceutical dosage forms for deferiprone and deferasirox combined therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
GB0223978D0 (en) 2002-10-15 2002-11-20 Novartis Ag Organic compound
KR20070022243A (ko) * 2004-04-08 2007-02-26 노파르티스 아게 데페라시록스 분산성 정제
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
CA2625112A1 (en) 2005-10-19 2007-04-26 Novartis Ag Dispersible tablets comprising deferasirox
WO2009067557A1 (en) 2007-11-19 2009-05-28 Teva Pharmaceutical Industries Ltd. Deferasirox pharmaceutical compositions
WO2009106824A2 (en) 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
WO2009130604A2 (en) * 2008-04-21 2009-10-29 Actavis Group Ptc Ehf Solid state forms of deferasirox salts and process for the preparation thereof
WO2010035282A1 (en) 2008-09-24 2010-04-01 Matrix Laboratories Limited Pharmaceutical compositions comprising deferasirox
WO2010143006A1 (en) 2009-06-10 2010-12-16 Carlo Ghisalberti Orally bioavailable iron chelators in the treatment of an inflammatory bowel disease
ES2543427T3 (es) * 2010-07-08 2015-08-19 Ratiopharm Gmbh Forma farmacéutica oral de deferasirox
KR20140011300A (ko) 2010-10-01 2014-01-28 시플라 리미티드 데페라시록스를 포함하는 약학 조성물
RS56890B1 (sr) 2013-03-08 2018-04-30 Novartis Ag Formulacije deferasiroksa za oralnu upotrebu
WO2017158559A1 (en) 2016-03-17 2017-09-21 Lupin Limited Compositions of deferasirox

Also Published As

Publication number Publication date
AU2017203897A1 (en) 2017-06-29
PL3124018T3 (pl) 2018-05-30
LT2964202T (lt) 2019-02-11
ES2708955T5 (es) 2023-11-10
DK3124018T3 (en) 2018-03-26
ES2663135T3 (es) 2018-04-11
JP2018162255A (ja) 2018-10-18
CA2890465A1 (en) 2014-09-12
SA515360425B1 (ar) 2018-01-21
EP2964202B2 (en) 2023-05-31
AU2014224198B2 (en) 2017-06-15
US9283209B2 (en) 2016-03-15
ES2708955T3 (es) 2019-04-12
ES2663135T5 (en) 2024-12-16
EP3124018A1 (en) 2017-02-01
ECSP15042897A (es) 2019-03-29
AU2017203897B2 (en) 2019-02-14
PL2964202T3 (pl) 2019-04-30
IL240797A0 (en) 2015-10-29
UY35367A (es) 2014-10-31
EA201591665A1 (ru) 2015-12-30
MY170303A (en) 2019-07-17
PH12015501981B1 (en) 2016-01-11
KR20170045391A (ko) 2017-04-26
RS58317B1 (sr) 2019-03-29
JP2016510068A (ja) 2016-04-04
HUE036921T2 (hu) 2018-08-28
US20170290811A1 (en) 2017-10-12
ZA201506060B (en) 2016-12-21
TWI686215B (zh) 2020-03-01
RS56890B1 (sr) 2018-04-30
TW201442742A (zh) 2014-11-16
AU2014224198A1 (en) 2015-09-10
US20160220493A1 (en) 2016-08-04
SG11201506491RA (en) 2015-09-29
PT2964202T (pt) 2019-02-06
CY1121315T1 (el) 2020-05-29
HRP20180387T1 (hr) 2018-04-20
CU20150110A7 (es) 2016-04-25
AP2015008668A0 (en) 2015-08-31
SI2964202T1 (sl) 2019-02-28
IL240797B (en) 2022-01-01
CL2015002495A1 (es) 2016-03-04
DOP2015000220A (es) 2015-11-30
LT3124018T (lt) 2018-03-12
PT3124018T (pt) 2018-03-22
TW201838623A (zh) 2018-11-01
EP2964202A1 (en) 2016-01-13
EP2964202B1 (en) 2018-10-31
HUE041224T2 (hu) 2019-05-28
TN2015000393A1 (en) 2017-01-03
CN105025886B (zh) 2019-01-15
HRP20190173T1 (hr) 2019-03-22
ME03297B (me) 2019-07-20
US20180221285A1 (en) 2018-08-09
BR112015021254A2 (pt) 2017-07-18
NI201500126A (es) 2015-11-18
JP2020180123A (ja) 2020-11-05
KR101925671B1 (ko) 2019-02-27
EA031719B1 (ru) 2019-02-28
JP6739470B2 (ja) 2020-08-12
WO2014136079A1 (en) 2014-09-12
CR20150467A (es) 2015-10-27
DK2964202T3 (en) 2019-02-25
EP3124018B1 (en) 2017-12-20
SG10201807204YA (en) 2018-09-27
PE20151600A1 (es) 2015-11-26
TWI625136B (zh) 2018-06-01
JO3570B1 (ar) 2020-07-05
MX2015011962A (es) 2016-07-07
EP3124018B2 (en) 2024-04-24
CY1120021T1 (el) 2018-12-12
JP6434429B2 (ja) 2018-12-05
CU24348B1 (es) 2018-05-08
CN105025886A (zh) 2015-11-04
HK1212242A1 (en) 2016-06-10
US20150017241A1 (en) 2015-01-15
KR20150126900A (ko) 2015-11-13
MX361055B (es) 2018-11-26
NZ711179A (en) 2018-07-27
PH12015501981A1 (en) 2016-01-11

Similar Documents

Publication Publication Date Title
SI3124018T1 (en) Oral formulations of deferasirox
NZ729172A (en) Combination formulation of two antiviral compounds
MY177741A (en) Pharmaceutical compositions compring 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one-lactate monohydrate.
SI2989100T1 (en) NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6
AR065096A1 (es) Preparacion solida
MX356111B (es) Composiciones farmaceuticas disuasorias de abuso, de liberacion inmediata.
SI2729130T1 (en) Combined formulations of darunavir
MX2013001985A (es) Formulaciones a base de nalbufina y sus usos
WO2016210003A3 (en) 17-hydroxyprogesterone ester-containing oral compositions and related methods
IN2013MU02206A (enExample)
BR112017012566A2 (pt) formulações farmacêuticas de inibidores de cinases relacionadas à tropomiosina (trk)
RU2011152105A (ru) Составы таблеток 3-цианохинолина и их применение
JP2015509539A5 (enExample)
PH12015500165A1 (en) Formulations and methods of manufacturing formulations for use in colonic evacuation
NZ727834A (en) Fast acting orally disintegrating film
SI2271348T1 (en) Oral tablet formulation of tetracycline compound
SI2914599T1 (en) The solid salt form as alpha-6-mPEG6-O-hydroxycodone as opioid agonists and its use
MX2015015681A (es) Composicion farmaceutica que comprende fingolimod.
MY167596A (en) Antibiotic formulations
HRP20171930T1 (hr) Analozi diazonamida
SI2805714T1 (en) A stable pharmaceutical composition comprising amorphous rosuvastatin calcium
RU2012100120A (ru) Акарицидная фармацевтическая композиция на основе соли четвертичного фосфония, замещенного динитробензофураксана и ксимедонгидрохлорида
WO2016123482A3 (en) Sustained-release oral dosage forms for low aqueous solubility compounds
WO2016187595A3 (en) Oral pharmaceutical composition of methylergonovine
WO2013054178A3 (en) Extended release pharmaceutical compositions containing carmabazepine